108 家港股药企成绩单！有人跌超千亿，有人暴涨 588%，石药、百济、复星、药明谁起谁落？
整体来看，上半年传统有产品收入的药企整体增长明显放缓，而刚刚步入商业化的药企业绩相对亮眼，但商业化仍难题仍然待解。营收的放缓并没有影响药企对研发的投入。大分子药物仍是各大药企研发的重点；小分子的创新也同样是药企愿 “下功夫” 的地方；细胞疗法、ADC、mRNA 药物、PROTAC 等前沿技术已不再是少数者的游戏，而是各大药企突破创新瓶颈的重要途径。
Source: E药经理人 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Like